Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Mgc Pharmaceuticals Limited LSE:MXC London Ordinary Share AU000000MXC6 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 2.5% 1.025 1.00 1.05 1.125 1.00 1.00 5,281,162 12:29:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 30

MGC Pharmaceuticals Limited Application for Admission to Trading

23/05/2022 10:43am

UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart

From May 2022 to Aug 2022

Click Here for more Mgc Pharmaceuticals Charts.


RNS Number : 4358M

MGC Pharmaceuticals Limited

23 May 2022

MGC Pharmaceuticals Ltd.

Compliance Release - Application for Admission to Trading

23 May 2022


MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company ') advises that it is applying for the admission to the Financial Conduct Authority's Official List, and to trading on the Main Market of the LSE for the following Fully Paid Ordinary Shares (Shares) recently issued by the Company. The Company is seeking admission to trading for these shares from 8:00am (GMT) on Friday 27 May 2022.

The Company advises that the details of the Shares for which these applications are being lodged are as follows:

-- 8,961,574 Shares issued as the final tranche of deferred purchase consideration to the vendors of MediCaNL Inc.


Authorised for release by the Chairman, for further information please contact:

 MGC Pharmaceuticals Ltd    MGC Pharmaceuticals Ltd 
  Roby Zomer                 David Lim 
  CEO & Managing Director    Company Secretary 
  +61 8 6382 3390            +61 8 6382 3390 
 UK Broker - Turner Pope    UK PR Advisors - Tavistock 
  Andy Thacker               Charles Vivian / Tim Pearson 
  +44 203 657 0050           +44 207 920 3150 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

May 23, 2022 05:43 ET (09:43 GMT)

1 Year Mgc Pharmaceuticals Chart

1 Year Mgc Pharmaceuticals Chart

1 Month Mgc Pharmaceuticals Chart

1 Month Mgc Pharmaceuticals Chart
ADVFN Advertorial
Your Recent History
Mgc Pharma..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220813 09:13:36